Immigrant background and medicine use for aches: national representative study of adolescents

Cantarero-Arévalo, Lourdes; Andersen, Anette; Kristiansen, Maria; Hansen, Ebba Holme

doi:10.1186/2052-3211-7-1

Cited by 16 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When stockouts occurred, the staff at the facilities substituted the missing ARV with other ARV formulations or regimens, referred patients to other centres, or asked them to return later. Similar coping strategies have been described in response to ART stockouts in Tanzania, leading to increased cost for patients, higher risk of treatment interruption and emergence of resistant strains [ 25 ]. TDF stockouts occurring in 2012 in South Africa led to initiation of patients with less optimal regimens, patients having to return more frequently and an increase in missed drug pick-ups [ 26 ].…”

Section: Discussionmentioning

confidence: 82%

Stockouts of HIV commodities in public health facilities in Kinshasa: Barriers to end HIV

et al. 2018

View full text Add to dashboard Cite

Stockouts of HIV commodities increase the risk of treatment interruption, antiretroviral resistance, treatment failure, morbidity and mortality. The study objective was to assess the magnitude and duration of stockouts of HIV medicines and diagnostic tests in public facilities in Kinshasa, Democratic Republic of the Congo. This was a cross-sectional survey involving visits to facilities and warehouses in April and May 2015. All zonal warehouses, all public facilities with more than 200 patients on antiretroviral treatment (ART) (high-burden facilities) and a purposive sample of facilities with 200 or fewer patients (low-burden facilities) in Kinshasa were selected. We focused on three adult ART formulations, cotrimoxazole tablets, and HIV diagnostic tests. Availability of items was determined by physical check, while stockout duration until the day of the survey visit was verified with stock cards. In case of ART stockouts, we asked the pharmacist in charge what the facility coping strategy was for patients needing those medicines. The study included 28 high-burden facilities and 64 low-burden facilities, together serving around 22000 ART patients. During the study period, a national shortage of the newly introduced first-line regimen Tenofovir-Lamivudine-Efavirenz resulted in stockouts of this regimen in 56% of high-burden and 43% of low-burden facilities, lasting a median of 36 (interquartile range 29–90) and 44 days (interquartile range 24–90) until the day of the survey visit, respectively. Each of the other investigated commodities were found out of stock in at least two low-burden and two high-burden facilities. In 30/41 (73%) of stockout cases, the commodity was absent at the facility but present at the upstream warehouse. In 30/57 (54%) of ART stockout cases, patients did not receive any medicines. In some cases, patients were switched to different ART formulations or regimens. Stockouts of HIV commodities were common in the visited facilities. Introduction of new ART regimens needs additional planning.

show abstract

Section: Discussionmentioning

confidence: 82%

Stockouts of HIV commodities in public health facilities in Kinshasa: Barriers to end HIV

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Treatment under a presumptive diagnosis in an endemic area implies a lower diagnostic specificity and administration of unnecessary antimalarial therapies [40], but also underdiagnoses of other severe diseases that present with fevers [41]. Even when the presumptive diagnosis is lower in Equatorial Guinea than other countries in the region [4,17], it is still necessary to reinforce the importance of administering antimalarial therapies with diagnostic confirmation.…”

Section: Discussionmentioning

confidence: 99%

“…Plasmodium falciparum resistance to artemisinin and its derivatives has spread in Southeast Asia and is threatening malaria control efforts. In sub-Saharan Africa, low or inadequate use of artemisinin combination therapies (ACTs) may increase the malaria burden and the risk of widespread parasite resistance [4] as presumptive treatment, co-medication, low ACTs quality, and the use of artemisinin monotherapy persists [5]. Artemisinin monotherapy can contribute to the emergence of resistance to ACTs and lead to treatment failure [6].…”

Section: Introductionmentioning

confidence: 99%

Failures in the case management of children with uncomplicated malaria in Bata district of Equatorial Guinea and associated factors

et al. 2019

View full text Add to dashboard Cite

Background In Equatorial Guinea, malaria continues to be one of the main causes of morbidity and mortality among children. The National Therapeutic Guide established artesunate-amodiaquine (ASAQ) as first-line treatment for uncomplicated malaria, but compliance with this treatment is low. The aim of this study was to assess, for the first time, the performance of public healthcare workers in the diagnosis and treatment of uncomplicated malaria, their compliance with first-line Malaria National Therapeutic Guide and the associated factors. Methods A cross-sectional survey was conducted at the nine public health facilities in the Bata District of Equatorial Guinea to assess the management of uncomplicated malaria in children < 15 years of age. Bivariate and multivariate statistical analyses were used to determine the recommended treatment compliance and related factors. Results A total of 227 children with uncomplicated malaria were recorded from 9 public health facilities. Most of the treatments prescribed (83.3%) did not follow the first-line treatment recommended for uncomplicated malaria. The diagnosis was established with parasite confirmation in 182 cases (80.2%). After adjustment for other variables, children under 2 months of age, the use of parasite confirmation to the diagnosis of malaria and being familiar with the national therapeutic guide were significantly associated with the prescription of the first-line recommended treatment. Cases attended at the hospital or in a health facility with ASAQ in the pharmacy at the time of the study were also more likely to be prescribed with the recommended treatment, but with non-significant association after adjustment for other variables. Conclusions This study identified the factors associated with the low compliance with the first-line treatment by the public healthcare facilities of Bata District of Equatorial Guinea. It seems necessary to improve case management of children with uncomplicated malaria; to reinforce the use of Malaria National Therapeutic Guide and to inform about the danger of using artemisinin monotherapy. Furthermore, it is crucial to provide recommended first-line treatment to the pharmacies of all public health facilities to ensure access to this treatment.

show abstract

“…6 , 8 Countries’ key contribution to global health and wealth is turning fundamental R&D into innovative treatments. 9 Investments in healthcare innovation are leading the way to solve emerging healthcare problems and driving contributions to the global economy. Significant investments over the past 10 years are beginning to pay off since it relates to the treatment of untreatable disorders and chronic diseases, one of the biggest cost drivers in the healthcare system today.…”

Section: Introductionmentioning

confidence: 99%

<p>Cost-Effectiveness Analysis of Spending on Research and Development to Address the Needs for Innovative Therapeutic Products in Indonesia</p>

Suwantika

Kautsar

Zakiyah

et al. 2020

TCRM

View full text Add to dashboard Cite

show abstract

Immigrant background and medicine use for aches: national representative study of adolescents

Cited by 16 publications

References 19 publications

Stockouts of HIV commodities in public health facilities in Kinshasa: Barriers to end HIV

Stockouts of HIV commodities in public health facilities in Kinshasa: Barriers to end HIV

Failures in the case management of children with uncomplicated malaria in Bata district of Equatorial Guinea and associated factors

<p>Cost-Effectiveness Analysis of Spending on Research and Development to Address the Needs for Innovative Therapeutic Products in Indonesia</p>

Contact Info

Product

Resources

About